Ignite Creation Date:
2024-05-06 @ 7:20 PM
Last Modification Date:
2024-10-26 @ 3:05 PM
Study NCT ID:
NCT05975320
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-08-03
First Post:
2023-07-27
Brief Title:
ORBIT Versus HAS-BLED Scores in Predicting Major Bleeding in Patients With Atrial Fibrillation Receiving Oral Anticoagulants
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
ORBIT Versus HAS-BLED Scores in Predicting Major Bleeding in Patients With Atrial Fibrillation Receiving Oral Anticoagulants
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Atrial fibrillation AF is type of arrhythmia characterized by an irregular and often rapid heartbeats it has strong associations with other cardiovascular diseases such as heart failure coronary artery disease CAD valvular heart disease diabetes mellitus thyrotoxicosis and hypertension
Atrial fibrillation is the most frequent cardiac arrhythmia It has been estimated that 6-12 million people worldwide will suffer this condition in the US by 2050 and 179 million people in Europe by 2060 Atrial fibrillation is a major risk factor for ischemic stroke and provokes important economic burden along with significant morbidity and mortality
AF is arrhythmia with the potential to cause thromboembolism Studies suggest that AF increases the risk of stroke five-folds Stroke prevention is central to the management of patients with atrial fibrillation AF and effective stroke prevention requires oral anticoagulation OAC Either a vitamin K antagonist VKA eg warfarin or a non-VKA oral anticoagulant NOAC
Its essential reach the balance between prevention of thromboembolic as well as bleeding events during the anticoagulant use
Atrial fibrillation is the most frequent cardiac arrhythmia It has been estimated that 6-12 million people worldwide will suffer this condition in the US by 2050 and 179 million people in Europe by 2060 Atrial fibrillation is a major risk factor for ischemic stroke and provokes important economic burden along with significant morbidity and mortality
AF is arrhythmia with the potential to cause thromboembolism Studies suggest that AF increases the risk of stroke five-folds Stroke prevention is central to the management of patients with atrial fibrillation AF and effective stroke prevention requires oral anticoagulation OAC Either a vitamin K antagonist VKA eg warfarin or a non-VKA oral anticoagulant NOAC
Its essential reach the balance between prevention of thromboembolic as well as bleeding events during the anticoagulant use
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None